The shadow of generic challenges has repeatedly loomed above copyright’s famous drug, Viagra, triggering questions about the future of connected drug investments. While first times saw substantial profits, the exclusivity lapse has opened the path for less expensive substitutes, potentially reducing profitability and presenting a significant ris… Read More